dc.contributor.author | Dorling, A | en_US |
dc.contributor.author | Rebollo-Mesa, I | en_US |
dc.contributor.author | Hilton, R | en_US |
dc.contributor.author | Peacock, JL | en_US |
dc.contributor.author | Vaughan, R | en_US |
dc.contributor.author | Gardner, L | en_US |
dc.contributor.author | Danzi, G | en_US |
dc.contributor.author | Baker, R | en_US |
dc.contributor.author | Clark, B | en_US |
dc.contributor.author | Thuraisingham, RC | en_US |
dc.contributor.author | Buckland, M | en_US |
dc.contributor.author | Picton, M | en_US |
dc.contributor.author | Martin, S | en_US |
dc.contributor.author | Borrows, R | en_US |
dc.contributor.author | Briggs, D | en_US |
dc.contributor.author | Horne, R | en_US |
dc.contributor.author | McCrone, P | en_US |
dc.contributor.author | Kelly, J | en_US |
dc.contributor.author | Murphy, C | en_US |
dc.date.accessioned | 2015-09-15T09:17:32Z | |
dc.date.available | 2014-01-06 | en_US |
dc.date.issued | 2014-01-21 | en_US |
dc.identifier.issn | 1745-6215 | en_US |
dc.identifier.other | ARTN 30 | en_US |
dc.identifier.uri | http://qmro.qmul.ac.uk/xmlui/handle/123456789/8664 | |
dc.description | © 2014 Dorling et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. | |
dc.relation.ispartof | TRIALS | en_US |
dc.subject | Human leukocyte antigen antibodies | en_US |
dc.subject | renal transplantation | en_US |
dc.subject | premature allograft failure | en_US |
dc.subject | chronic rejection | en_US |
dc.subject | screening | en_US |
dc.subject | tacrolimus | en_US |
dc.subject | mycophenolate mofetil | en_US |
dc.subject | clinical trial | en_US |
dc.subject | randomised controlled trial | en_US |
dc.subject | randomized controlled trial | en_US |
dc.subject | KCTU | en_US |
dc.subject | CTU | en_US |
dc.subject | trials unit | en_US |
dc.subject | diabetes | en_US |
dc.subject | kidney | en_US |
dc.subject | graft failure | en_US |
dc.subject | biomarker | en_US |
dc.subject | biomarker-led care | en_US |
dc.subject | DSA | en_US |
dc.subject | non-DSA | en_US |
dc.subject | multicentre | en_US |
dc.subject | immunosuppression | en_US |
dc.subject | usual care | en_US |
dc.subject | treatment as usual | en_US |
dc.subject | standard care | en_US |
dc.subject | blinded | en_US |
dc.subject | unblinded | en_US |
dc.subject | EME funded | en_US |
dc.subject | NIHR | en_US |
dc.subject | optimised | en_US |
dc.subject | optimized | en_US |
dc.subject | intention-to-treat | en_US |
dc.subject | per protocol | en_US |
dc.title | Can a combined screening/treatment programme prevent premature failure of renal transplants due to chronic rejection in patients with HLA antibodies: study protocol for the multicentre randomised controlled OuTSMART trial | en_US |
dc.type | Article | |
dc.identifier.doi | 10.1186/1745-6215-15-30 | en_US |
pubs.author-url | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000333465400002&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=612ae0d773dcbdba3046f6df545e9f6a | en_US |
pubs.notes | Not known | en_US |
pubs.publication-status | Published | en_US |
pubs.volume | 15 | en_US |